Who founded Novosteo?

Novosteo was founded by Philip S. Low, Ph.D. in 2017.

Who are Novosteo's investors?

Novosteo's investors include Breakout Ventures, Elevate Ventures, Pfizer Venture Investments.

How much funding has Novosteo raised?

Novosteo has disclosed $17.7M raised across 1 of its 2 known rounds.

Where is Novosteo headquartered?

Novosteo is headquartered in West Lafayette, US.

Novosteo

West Lafayette, US · Founded 2017 · Delaware corporation · 16 employees on LinkedIn · 4 known investors

Find your way into Novosteo

Paths you didn't know you had: your email and LinkedIn already hold routes to the Novosteo team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T). The company focuses on treatments for rare and debilitating diseases.

Biotech Healthtech

Founders & leadership

Novosteo was founded in 2017 by Philip S. Low, Ph.D..

Philip S. Low, Ph.D.Founder

David LamondNamed on SEC filing

Daniel HaslerNamed on SEC filing

Dirk Thye, M.D.Named on SEC filing

William J. RutterNamed on SEC filing

Alex AndrianopoulosNamed on SEC filing

Investors · 4

Breakout Ventureslisted by Breakout VenturesSan Francisco · $500K – $6M

How we know: Breakout Ventures's portfolio page · Not right? Tell us

Elevate Ventureslisted by Elevate VenturesIndianapolis · $20K – $2M

How we know: the VCSheet dataset · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

Also in the syndicate · 1

Research Bridge Partners

Funding

SEC filings, press & company announcements

$17.7M disclosed across 1 of 2 rounds · 2019–2020

Undisclosed amountSeedAug 2019
Research Bridge Partners
Source ↗

▶$17.7MraisedApr 2022 · 37 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David LamondDirector
Daniel HaslerDirector
Dirk Thye, M.D.Executive Officer, Director
William J. RutterDirector
Alex AndrianopoulosDirector
Philip S. Low, Ph.D.Executive Officer, Director

Offering amount: $17.7M
Amount sold: $17.7M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

QuinceQuince is a direct-to-consumer clothing and home goods brand that sells sustainably manufactured essentials at affordable prices by eliminating supply chain intermediaries. The company sources premium materials like organic cotton and recycled polyester from ethical factories and sells directly to consumers, emphasizing quality, sustainability, and fair labor practices.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies working in the same space as Novosteo.

Frequently asked questions

What does Novosteo do?: Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T). The company focuses on treatments for rare and debilitating diseases.
Who founded Novosteo?: Novosteo was founded by Philip S. Low, Ph.D. in 2017.
Who are Novosteo's investors?: Novosteo's investors include Breakout Ventures, Elevate Ventures, Pfizer Venture Investments.
How much funding has Novosteo raised?: Novosteo has disclosed $17.7M raised across 1 of its 2 known rounds.
Where is Novosteo headquartered?: Novosteo is headquartered in West Lafayette, US.